Search Results

You are looking at 191 - 200 of 1,450 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Cary P. Gross, Craig S. Meyer, Sarika Ogale, Matthew Kent, and William B. Wong

first evidence of treatment ≥4 months from their advanced diagnosis date. Patient attrition is shown in supplemental eTable 1 (available with this article at JNCCN.org ). Construction of Variables Clinical characteristics included demographics

Full access

Jamie M. Jacobs, Molly E. Ream, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Joanne Buzaglo, Inga T. Lennes, Steven A. Safren, William F. Pirl, Jennifer S. Temel, and Joseph A. Greer

. Research staff collected information about cancer diagnosis, oral therapy type, and other clinical characteristics from the EHR. Electronic Adherence Monitoring Participants were asked to store their oral therapy medication in pill bottles with electronic

Full access

John H. Strickler, Ling-I Hsu, Phoebe Wright, Michael Stecher, Muriel F. Siadak, Maria Corinna Palanca-Wessels, Junhua Yu, Nicole Zhang, Carin R. Espenschied, Kathryn Lang, and Tanios S. Bekaii-Saab

from index date), and provider-confirmed mCRC status via requisition form on the date of the G360 test. Outcomes Assessed Patient characteristics collected at index date were age, sex, year of index, geographic location (state), payer type

Full access

Alice Dragomir, Nawar Touma, Jason Hu, Sylvie Perreault, and Armen G. Aprikian

account for differences in the distribution of baseline characteristics between treatment groups, a propensity score method was used to reduce the effect of potential confounding. 12 , 13 First, the inverse probability of treatment weighting (IPTW) using

Full access

Deborah K. Armstrong

patients receive chemotherapy with paclitaxel and carboplatin. In early-stage nonserous epithelial ovarian cancer, 3 cycles have been shown to be as effective as 6 Figure 1. Characteristics of ovarian cancer subtypes. Abbreviation: MP

Full access

Arif H. Kamal, Steve Power, Gloria Broadwater, Audrey R. Holland, and Paul K. Marcom

with patient characteristics, these profiles ensure that targeted therapies are selectively applied in delivering patient-centered care. A shining example of this has been the incorporation of trastuzumab for cancers that overexpress HER2, the use of

Full access

Joyce Valerie Veld, Femke Julie Amelung, Wernard Aat Antoine Borstlap, Emo Eise van Halsema, Esther Catharina Josephina Consten, Peter Derk Siersema, Frank ter Borg, Edwin Silvester van der Zaag, Paul Fockens, Willem Adrianus Bemelman, Jeanin Elise van Hooft, Pieter Job Tanis, and for the Dutch Snapshot Research Group

, potential eligible patients were first identified through the DCRA, and collaborators in each participating hospital were provided with their own patients registered in the DCRA. Subsequently, collaborators extended baseline characteristics and short

Full access

Lara Franziska Stolzenbach, Giuseppe Rosiello, Angela Pecoraro, Carlotta Palumbo, Stefano Luzzago, Marina Deuker, Zhe Tian, Anne-Sophie Knipper, Raisa Pompe, Kevin C. Zorn, Shahrokh F. Shariat, Felix K.H. Chun, Markus Graefen, Fred Saad, and Pierre I. Karakiewicz

version 3.4.1 (R Foundation for Statistical Computing). All tests were 2-sided with a level of significance set at P <.05. Results Descriptive Characteristics Of all 210,100 patients treated with RP, 4,704 (2.2%), 17,785 (8.4%), and 11,040 (5

Full access

Fang-Shu Ou, Daniel J. Walden, Joseph J. Larson, Sandra Kang, Cassia R. Griswold, Benjamin E. Ueberroth, Bhamini Patel, Amber Draper, Puneet Raman, Olatunji B. Alese, Mohamad B. Sonbol, Tanios S. Bekaii-Saab, Christina S. Wu, and Daniel H. Ahn

chemotherapy between January 1, 2016, and January 31, 2021, were included in the analysis. Patients’ demographic and disease characteristics, treatment details (including chemotherapy regimen, intended duration, and dose reductions), trAEs, recurrence status

Full access

Alimujiang Wushou, Meng Wang, Feiluore Yibulayin, Lei Feng, Meng-meng Lu, Yuan Luo, Hui Liu, and Zhi-cheng Yang

resection of the primary tumor, in consideration of postoperative recurrence and poor prognosis due to the high rate of occult cervical metastasis in early OSCC. 13 Because of the lack of consensus in characteristics, study populations, and patient